113 related articles for article (PubMed ID: 26408680)
1. Genes Involved in Maintaining the Bone Marrow Stroma Are Dysregulated in Patients with Myelofibrosis: Lenalidomide Treatment Up-regulates SOCS3.
Livun A; Newberry KJ; Manshouri T; Kusec R; Verstovsek S
Anticancer Res; 2015 Oct; 35(10):5219-23. PubMed ID: 26408680
[TBL] [Abstract][Full Text] [Related]
2. Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis.
Chihara D; Masarova L; Newberry KJ; Maeng H; Ravandi F; Garcia-Manero G; Ferrajoli A; Cortes J; Kantarjian H; Verstovsek S
Leuk Res; 2016 Sep; 48():1-5. PubMed ID: 27416326
[TBL] [Abstract][Full Text] [Related]
3. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.
Quintás-Cardama A; Kantarjian HM; Manshouri T; Thomas D; Cortes J; Ravandi F; Garcia-Manero G; Ferrajoli A; Bueso-Ramos C; Verstovsek S
J Clin Oncol; 2009 Oct; 27(28):4760-6. PubMed ID: 19720904
[TBL] [Abstract][Full Text] [Related]
4. Thalidomide and lenalidomide in primary myelofibrosis.
Holle N; de Witte T; Mandigers C; Schaap N; Raymakers R
Neth J Med; 2010 Aug; 68(1):293-8. PubMed ID: 20739725
[TBL] [Abstract][Full Text] [Related]
5. Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903.
Mesa RA; Yao X; Cripe LD; Li CY; Litzow M; Paietta E; Rowe JM; Tefferi A; Tallman MS
Blood; 2010 Nov; 116(22):4436-8. PubMed ID: 20651074
[TBL] [Abstract][Full Text] [Related]
6. Comparison of thalidomide and lenalidomide as therapy for myelofibrosis.
Jabbour E; Thomas D; Kantarjian H; Zhou L; Pierce S; Cortes J; Verstovsek S
Blood; 2011 Jul; 118(4):899-902. PubMed ID: 21622644
[TBL] [Abstract][Full Text] [Related]
7. [Effectiveness and safety of lenalidomide in myelofibrosis patients: a case series from the Spanish compassionate use program].
Castillo I; Ojea MA; Boqué C; Asensio A; Hermosilla MM; Blanes M;
Farm Hosp; 2013; 37(2):135-42. PubMed ID: 23789757
[TBL] [Abstract][Full Text] [Related]
8. Treatment of deletion 5q acute myeloid leukemia with lenalidomide.
Lancet JE; List AF; Moscinski LC
Leukemia; 2007 Mar; 21(3):586-8. PubMed ID: 17230228
[No Abstract] [Full Text] [Related]
9. Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis.
Daver N; Cortes J; Newberry K; Jabbour E; Zhou L; Wang X; Pierce S; Kadia T; Sasaki K; Borthakur G; Ravandi F; Pemmaraju N; Kantarjian H; Verstovsek S
Haematologica; 2015 Aug; 100(8):1058-63. PubMed ID: 26088933
[TBL] [Abstract][Full Text] [Related]
10. Chromosome 5q deletion is extremely rare in patients with myelofibrosis.
Takahashi K; Cortes J; Pierce S; Abruzzo L; Kantarjian H; Verstovsek S
Leuk Res; 2013 May; 37(5):552-5. PubMed ID: 23391517
[TBL] [Abstract][Full Text] [Related]
11. [Research and Applications Progress of Lenalidomide for Myelofibrosis--Review].
Fan WJ; Wu T; Chen JW; Bai H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Dec; 26(6):1854-1857. PubMed ID: 30501733
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia.
Daver N; Shastri A; Kadia T; Newberry K; Pemmaraju N; Jabbour E; Zhou L; Pierce S; Cortes J; Kantarjian H; Verstovsek S
Leuk Res; 2014 Sep; 38(9):1126-9. PubMed ID: 25047979
[TBL] [Abstract][Full Text] [Related]
13. Methylation-associated dysregulation of the suppressor of cytokine signaling-3 gene in multiple myeloma.
Wilop S; van Gemmeren TB; Lentjes MH; van Engeland M; Herman JG; Brümmendorf TH; Jost E; Galm O
Epigenetics; 2011 Aug; 6(8):1047-52. PubMed ID: 21934357
[TBL] [Abstract][Full Text] [Related]
14. Changes associated with lenalidomide treatment in the gene expression profiles of patients with del(5q).
Belickova M; Cermak J; Dostalova Merkerova M; Vesela J; Krejcik Z; Cechova E; Zemanova Z; Michalova K; Votavova H; Caniga M; Neuwirtova R; Jonasova A
Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):375-83. PubMed ID: 22608605
[TBL] [Abstract][Full Text] [Related]
15. Experience with lenalidomide in an Austrian non-study population with advanced myelofibrosis.
Burgstaller S; Fridrik M; Hojas S; Kühr T; Ludwig H; Mayrbäurl B; Pöhnl R; Pötscher M; Schlögl E; Zauner D; Thaler J; Gisslinger H
Wien Klin Wochenschr; 2013 Apr; 125(7-8):196-9. PubMed ID: 23536018
[TBL] [Abstract][Full Text] [Related]
16. Lenalidomide therapy in myelofibrosis with myeloid metaplasia.
Tefferi A; Cortes J; Verstovsek S; Mesa RA; Thomas D; Lasho TL; Hogan WJ; Litzow MR; Allred JB; Jones D; Byrne C; Zeldis JB; Ketterling RP; McClure RF; Giles F; Kantarjian HM
Blood; 2006 Aug; 108(4):1158-64. PubMed ID: 16609064
[TBL] [Abstract][Full Text] [Related]
17. Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions.
Tefferi A; Lasho TL; Mesa RA; Pardanani A; Ketterling RP; Hanson CA
Leukemia; 2007 Aug; 21(8):1827-8. PubMed ID: 17460705
[No Abstract] [Full Text] [Related]
18. Improvement of Anaemia in Patients with Primary Myelofibrosis by Low-Dose Thalidomide and Prednisone.
Bělohlávková P; Maisnar V; Voglová J; Buchler T; Žák P
Acta Medica (Hradec Kralove); 2016; 59(2):50-3. PubMed ID: 27526305
[TBL] [Abstract][Full Text] [Related]
19. Mini-dose of thalidomide for treatment of primary myelofibrosis. Report of a case with complete reversal of bone marrow fibrosis and splenomegaly.
Berrebi A; Feldberg E; Spivak I; Shvidel L
Haematologica; 2007 Feb; 92(2):e15-6. PubMed ID: 17405746
[TBL] [Abstract][Full Text] [Related]
20. Differential diagnosis of myelofibrosis based on WHO 2008 criteria: acute panmyelosis with myelofibrosis, acute megakaryoblastic leukemia with myelofibrosis, primary myelofibrosis and myelodysplastic syndrome with myelofibrosis.
Bae E; Park CJ; Cho YU; Seo EJ; Chi HS; Jang S; Lee KH; Lee JH; Lee JH; Suh JJ; Im HJ
Int J Lab Hematol; 2013 Dec; 35(6):629-36. PubMed ID: 23693053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
